Brief: ABVC Biopharma Provides Vitargus Update
30/06/2022 13:31
June 30 (Reuters) - ABVC Biopharma Inc ABVC.O :
* ABVC BIOPHARMA PROVIDES VITARGUS® UPDATE
* ABVC BIOPHARMA - VITARGUS PHASE II CLINICAL STUDY PROTOCOL
BEEN
APPROVED BY CENTRAL RESEARCH ETHICS COMMITTEE OF NATIONAL
RESEARCH COUNCIL OF THAILAND
Source text for Eikon: ID:nGNX11GYkH
Further company coverage: ABVC.O
Recent news on ABVC Biopharma
See all newsBrief: ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon
Brief: Abvc Biopharma Inc Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: ABVC Biopharma Concluded That Financial Statements For FY Ended Dec 31, 2023 Should No Longer Be Relied Upon Due To Errors In Financial Statements
Brief: ABVC Biopharma Inc On March 5, Leeds Chow Resigns As CFO Of Abvc Biopharma
Brief: ABVC Biopharma Secures $200,000 In First Cash Licensing Payment From Oncology Products Partner